Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Phase 2 Recruiting
65 enrolled
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase 2 Completed
83 enrolled 17 charts
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Phase 2 Completed
647 enrolled 17 charts
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Phase 2 Completed
46 enrolled 13 charts
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
46 enrolled 13 charts
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
Phase 2 Terminated
50 enrolled 27 charts
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Phase 2 Completed
188 enrolled 16 charts
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Phase 2 Terminated
59 enrolled 16 charts
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
37 enrolled 13 charts
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
55 enrolled 16 charts
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Phase 2 Completed
38 enrolled 10 charts
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Phase 2 Completed
89 enrolled 28 charts
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Phase 2 Completed
56 enrolled 10 charts
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
27 enrolled 8 charts
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Phase 2 Completed
40 enrolled 16 charts
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Phase 2 Completed
30 enrolled
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Phase 2 Completed
45 enrolled 18 charts
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Phase 2 Terminated
6 enrolled 8 charts
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Phase 2 Terminated
10 enrolled 6 charts
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Phase 2 Completed
56 enrolled 9 charts
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Phase 2 Completed
143 enrolled 9 charts
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2 Completed
35 enrolled
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
Phase 2 Completed
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Phase 2 Unknown
73 enrolled
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2 Unknown
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Phase 2 Completed
171 enrolled
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2 Completed
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
Phase 2 Terminated
110 enrolled
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase 2 Completed
78 enrolled
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Phase 2 Completed
48 enrolled
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
Phase 2 Completed
40 enrolled
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
Phase 2 Completed
65 enrolled
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Phase 2 Completed
55 enrolled
Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
Phase 2 Terminated
80 enrolled
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Phase 2 Completed
51 enrolled
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
Phase 2 Unknown
47 enrolled